STOCK TITAN

Omeros Corporation - OMER STOCK NEWS

Welcome to our dedicated news page for Omeros Corporation (Ticker: OMER), a resource for investors and traders seeking the latest updates and insights on Omeros Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Omeros Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Omeros Corporation's position in the market.

Rhea-AI Summary
Omeros announced financial results for Q4 and year-end 2023, with a net loss of $9.1 million in Q4, compared to $37.8 million in the previous quarter. The company reported a net loss of $117.8 million for the full year, including a $200.0 million milestone payment. Omeros also secured $115.5 million in cash from an amended OMIDRIA royalty purchase agreement with DRI Healthcare Acquisitions LP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.39%
Tags
-
Rhea-AI Summary
Omeros (NASDAQ: OMER) will release its financial results for the quarter and year ended December 31, 2023, on April 1, 2024. A conference call and webcast will follow to discuss the results and recent developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
-
Rhea-AI Summary
Omeros Corporation (OMER) announces the upcoming presentation of a report on narsoplimab treatment for TA-TMA. The report will be presented at the 2024 Tandem Meetings by U.S. investigators. Narsoplimab targets MASP-2 and will be featured as a poster presentation in San Antonio, Texas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.7%
Tags
conferences
Rhea-AI Summary
Omeros Corporation announced an expanded deal with DRI Healthcare Acquisitions LP, resulting in a $115 million upfront payment and the potential for an additional $55 million in sales-based milestones. This deal involves an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States, which is a novel ophthalmic product for use in cataract and lens replacement surgery. The expanded agreement extends Omeros' operating runway and provides substantial additional non-dilutive working capital. Omeros retains the upside of all ex-U.S. royalties and, after 2031, of all global royalties from OMIDRIA sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
none
-
Rhea-AI Summary
Omeros Corporation (Nasdaq: OMER) announced Q3 financial results, including a net loss of $37.8 million, and recent developments in their clinical-stage biopharmaceutical programs. Highlights include discontinuation of the Phase 3 ARTEMIS-IGAN clinical trial, resubmission plans for the BLA for narsoplimab in TA-TMA, and advancements in OMS906 and OMS527 programs. The company also expects to pay the $95 million principal balance due at maturity of their unsecured convertible senior notes on November 15, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
-
Rhea-AI Summary
Omeros Corporation (NASDAQ: OMER) will release its financial results for the quarter ended September 30, 2023, on November 9, 2023. The company will host a conference call and webcast on the same day to discuss the financial results and recent developments. The conference call details are available on Omeros' website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
Rhea-AI Summary
Omeros Corporation announces the online publication of a report on the treatment of patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) using narsoplimab. The report will be presented at the Annual Meeting of the American Society of Hematology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
none
-
Rhea-AI Summary
Omeros Corporation announced that two abstracts on OMS906, an investigational inhibitor of MASP-3, will be presented at the 65th Annual Meeting of the American Society of Hematology. The abstracts discuss the normalization of hemoglobin levels and increased clone size in treatment-naïve PNH patients, as well as the effective inhibition of complement-mediated hemolysis in preclinical models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.96%
Tags
conferences
-
Rhea-AI Summary
Omeros Corporation appoints Andreas Grauer as chief medical officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.64%
Tags
management
Rhea-AI Summary
Omeros Corporation provides update on ARTEMIS-IGAN trial for narsoplimab in IgA nephropathy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.16%
Tags
Omeros Corporation

Nasdaq:OMER

OMER Rankings

OMER Stock Data

217.86M
51.71M
4.38%
43.22%
22.93%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Seattle

About OMER

omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.